Objective To investigate the current state of clinical diagnosis and treatment for cervical cancer in China，focusing on systemic therapeutic practices. By surveying clinicians on biomarker testing applications，treatment regimen considerations and preferences，this study is aimed to identify unmet clinical needs and provide a reference for standardization of diagnosis and treatment. Methods A nationwide sampling survey combining online questionnaires and in-depth interviews was conducted from August to September 2025，involving 300 clinicians （30 experts participated in interviews，270 completed questionnaires）. The survey primarily covered the admission of cervical cancer patients，patient stage and pathology types，biomarker testing，treatment strategies for locally advanced，recurrent，or metastatic cervical cancer （including first-，second- or later-line settings）. It also covered clinicians’ insights regarding immune checkpoint inhibitors （ICI） and antibody-drug conjugates （ADC）. Results A total of 270 valid questionnaires and 30 valid expert interviews were obtained. At diagnosis，early-stage （ⅠA1-ⅠB2，ⅡA1），locally advanced （ⅠB3，ⅡA2-ⅣA），and recurrent/metastatic （ⅣB） cervical cancer （r/m CC） accounted for 32.2%，35.8%，and 31.9%，respectively. Squamous cell carcinoma was predominant （74.9%）. Among the patients，75.0% were recommended for programmed death-ligand 1 （PD-L1） and other biomarker testing，with an actual testing rate of 53.7%. For locally advanced cervical cancer，concurrent chemoradiotherapy （CCRT） with or without ICIs was the first choice. For r/m CC，first-line treatment was mainly ICI combined with chemotherapy±anti-angiogenic agents （71%）. For second- or later-line treatment，combination regimens predominated （approximately 75%）. Among patients not previously treated with ICIs，chemotherapy combined with ICIs was the first choice，with chemotherapy combined with ICIs and chemotherapy combined with anti-angiogenic agents accounting for 37% and 34% of cases，respectively. For patients with prior ICI exposure，chemotherapy combined with ICIs and chemotherapy combined with anti-angiogenic agents were the first choices at 30% and 23%，respectively；regimens containing ADCs accounted for approximately 30%. Conclusions This study reveals the current status of cervical cancer diagnosis and treatment in China，highlighting gaps in biomarker testing recommendations and clinical application. It identifies core considerations and treatment options for locally advanced and r/m CC in first-line，providing data support for advancing standardized clinical practice.